Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The evaluation of DNA-linked inhibitor antibody and AlphaScreen assays for high-throughput screening of compounds targeting the cap-binding domain in influenza a polymerase

K. Čermáková, J. Gregor, M. Kráľ, E. Karlukova, V. Navrátil, R. Reiberger, CB. Albiñana, V. Bechynský, P. Majer, J. Konvalinka, A. Machara, M. Kožíšek

. 2025 ; 205 (-) : 106990. [pub] 20241212

Language English Country Netherlands

Document type Journal Article

The PB2 subunit of the influenza virus polymerase complex is essential for viral replication, primarily through a mechanism known as cap-snatching. In this process, PB2 binds to the 5' cap structure of host pre-mRNAs, enabling the viral polymerase to hijack the host transcriptional machinery. This binding facilitates the cleavage and integration of the capped RNA fragment into viral mRNA, thereby promoting efficient viral replication. Inhibiting the PB2-cap interaction is therefore crucial, as it directly disrupts the viral replication cycle. Consequently, targeting PB2 with specific inhibitors is a promising strategy for antiviral drug development against influenza. However, there are currently no available methods for the high-throughput screening of potential inhibitors. The development of new inhibitor screening methods of potential PB2 binders is the focus of this study. In this study, we present two novel methods, DIANA and AlphaScreen, for screening influenza PB2 cap-binding inhibitors and evaluate their effectiveness compared to the established differential scanning fluorimetry (DSF) technique. Using a diverse set of substrates and compounds based on the previously described PB2 binder pimodivir, we thoroughly assessed the capabilities of these new methods. Our findings demonstrate that both DIANA and AlphaScreen are highly effective for PB2 inhibitor screening, offering distinct advantages over traditional techniques such as isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR). These advantages include improved scalability, reduced sample requirements, and the capacity for label-free detection. Notably, DIANA's ability to determine Ki values from a single-well measurement significantly enhances its practicality and efficiency in inhibitor screening. This research represents a significant step forward in the development of more efficient and scalable screening strategies, helping advance efforts in the discovery of antiviral drugs against influenza.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010069
003      
CZ-PrNML
005      
20250429134610.0
007      
ta
008      
250415e20241212ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejps.2024.106990 $2 doi
035    __
$a (PubMed)39674552
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Čermáková, Kateřina $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic; First Faculty of Medicine, Charles University, Kateřinská 1660, 121 08, Prague 2, Czech Republic
245    14
$a The evaluation of DNA-linked inhibitor antibody and AlphaScreen assays for high-throughput screening of compounds targeting the cap-binding domain in influenza a polymerase / $c K. Čermáková, J. Gregor, M. Kráľ, E. Karlukova, V. Navrátil, R. Reiberger, CB. Albiñana, V. Bechynský, P. Majer, J. Konvalinka, A. Machara, M. Kožíšek
520    9_
$a The PB2 subunit of the influenza virus polymerase complex is essential for viral replication, primarily through a mechanism known as cap-snatching. In this process, PB2 binds to the 5' cap structure of host pre-mRNAs, enabling the viral polymerase to hijack the host transcriptional machinery. This binding facilitates the cleavage and integration of the capped RNA fragment into viral mRNA, thereby promoting efficient viral replication. Inhibiting the PB2-cap interaction is therefore crucial, as it directly disrupts the viral replication cycle. Consequently, targeting PB2 with specific inhibitors is a promising strategy for antiviral drug development against influenza. However, there are currently no available methods for the high-throughput screening of potential inhibitors. The development of new inhibitor screening methods of potential PB2 binders is the focus of this study. In this study, we present two novel methods, DIANA and AlphaScreen, for screening influenza PB2 cap-binding inhibitors and evaluate their effectiveness compared to the established differential scanning fluorimetry (DSF) technique. Using a diverse set of substrates and compounds based on the previously described PB2 binder pimodivir, we thoroughly assessed the capabilities of these new methods. Our findings demonstrate that both DIANA and AlphaScreen are highly effective for PB2 inhibitor screening, offering distinct advantages over traditional techniques such as isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR). These advantages include improved scalability, reduced sample requirements, and the capacity for label-free detection. Notably, DIANA's ability to determine Ki values from a single-well measurement significantly enhances its practicality and efficiency in inhibitor screening. This research represents a significant step forward in the development of more efficient and scalable screening strategies, helping advance efforts in the discovery of antiviral drugs against influenza.
650    12
$a rychlé screeningové testy $x metody $7 D057166
650    12
$a antivirové látky $x farmakologie $x chemie $7 D000998
650    12
$a virové proteiny $x antagonisté a inhibitory $x metabolismus $7 D014764
650    _2
$a virus chřipky A $x účinky léků $7 D009980
650    _2
$a RNA čepičky $x metabolismus $7 D012315
650    _2
$a RNA-dependentní RNA-polymerasa $x antagonisté a inhibitory $x metabolismus $7 D012324
650    _2
$a lidé $7 D006801
650    _2
$a fluorometrie $x metody $7 D005470
650    _2
$a piperidiny $x farmakologie $7 D010880
650    _2
$a pyridiny $7 D011725
650    _2
$a pyrimidiny $7 D011743
650    _2
$a pyrroly $7 D011758
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gregor, Jiří $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic; First Faculty of Medicine, Charles University, Kateřinská 1660, 121 08, Prague 2, Czech Republic
700    1_
$a Kráľ, Michal $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic; First Faculty of Medicine, Charles University, Kateřinská 1660, 121 08, Prague 2, Czech Republic
700    1_
$a Karlukova, Elena $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic
700    1_
$a Navrátil, Václav $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic
700    1_
$a Reiberger, Róbert $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic; Faculty of Science, Charles University, Hlavova 8, 128 00, Prague 2, Czech Republic
700    1_
$a Albiñana, Carlos Berenguer $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic
700    1_
$a Bechynský, Vít $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic
700    1_
$a Majer, Pavel $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic
700    1_
$a Konvalinka, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic; Faculty of Science, Charles University, Hlavova 8, 128 00, Prague 2, Czech Republic
700    1_
$a Machara, Aleš $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic. Electronic address: ales.machara@uochb.cas.cz
700    1_
$a Kožíšek, Milan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 166 10, Prague 6, Czech Republic. Electronic address: milan.kozisek@uochb.cas.cz
773    0_
$w MED00001639 $t European journal of pharmaceutical sciences $x 1879-0720 $g Roč. 205 (20241212), s. 106990
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39674552 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134606 $b ABA008
999    __
$a ok $b bmc $g 2311437 $s 1247150
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 205 $c - $d 106990 $e 20241212 $i 1879-0720 $m European journal of pharmaceutical sciences $n Eur J Pharm Sci $x MED00001639
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...